Forte Biosciences, Inc. (FBRX)

US — Healthcare Sector
Peers: INDP  RZLT  TPST  CMRA  ABVC  KTTA  BTTX  ZIVO  THRX  ERAS  AMTI  HOWL  EWTX  DBTX  CELC  CCCC 

Automate Your Wheel Strategy on FBRX

With Tiblio's Option Bot, you can configure your own wheel strategy including FBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FBRX
  • Rev/Share 0.0
  • Book/Share 3.3711
  • PB 2.4858
  • Debt/Equity 0.0
  • CurrentRatio 5.2212
  • ROIC -1.1699

 

  • MktCap 55168724.0
  • FreeCF/Share -3.0288
  • PFCF -1.5979
  • PE -2.1852
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -1.4915

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation FBRX TD Cowen -- Buy -- -- Jan. 21, 2025

News

About Forte Biosciences, Inc. (FBRX)

  • IPO Date 2017-04-13
  • Website https://www.fortebiorx.com
  • Industry Biotechnology
  • CEO Dr. Paul A. Wagner Ph.D.
  • Employees 14
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.